Iterative Reconstruction in Dose Reduction of A Head CT Examination and Corresponding Acquisition Parameter Selection.

PURPOSE: To investigate the potential of iterative reconstruction in radiation dose reduction during head computed tomography (CT) examinations and to evaluate the relationship between the parameters milliampere second (mAs), kilovoltage (kV), and iterative reconstruction strength using a live ovine (sheep) model. METHODS: A sheep was scanned on a SOMATOM Force (Siemens Healthineers) CT scanner at 12 mAs and 3 kV. Images were reconstructed with filtered back projection (FBP) and the Advanced Modeled Iterative Reconstruction (ADMIRE; Siemens Healthineers) strengths 1 to 5. Images with 216 combinations of varying doses, kVs, and reconstructions were rated by 2 neuroradiologists for low-contrast detectability (ie, gray-white matter differentiation) and image texture. RESULTS: Using only gray-white matter differentiation, maximum dose reduction was 75% at 100 kV with ADMIRE-3, and using only image texture, maximum dose reduction was 75% at 120 kV (and 140 kV) with ADMIRE-5. When these 2 metrics were combined, maximum dose reduction was 50% at 120 kV with ADMIRE-3. Other kV levels and higher iterative reconstruction strengths did not offer superior results. DISCUSSION: Although artificial intelligence algorithms are certainly gaining momentum, iterative reconstruction technology likely will remain more accessible to most hospitals and imaging centers. Dose reduction with preservation of image quality (ie, gray-white differentiation and image texture) can be achieved when complemented by appropriate iterative reconstruction strength. However, the effect of iterative reconstruction strength on gray-white differentiation and image texture does not necessarily converge on the same pattern. CONCLUSION: Maximum dose reduction was 50% at 120 kV with ADMIRE-3, which confirms the potential for dose reduction with appropriately chosen iterative reconstruction strength and reveals a preference for 120 kV, as well as a limit to dose reduction by further increasing iterative reconstruction strength. A better understanding of dose-voltage-reconstruction relationships in iterative reconstruction might allow for greater dose reductions than current practices allow.

The use of intraosseous needles for injection of contrast media for computed tomographic angiography of the thoracic aorta.

BACKGROUND: The objective of this study is to evaluate the safety and quality of computed tomographic angiography of the thoracic aorta (CTA-TA) exams performed using intraosseous needle intravenous access (ION-IVA) for contrast media injection (CMI). METHODS: All CTA-TA exams at the study institution performed between 1/1/2013 and 8/14/2015 were reviewed retrospectively to identify those exams which had been performed using ION-IVA (ION-exams). ION-exams were then analyzed to determine aortic attenuation and contrast-to-noise ratio (CNR). Linear regression was used to determine how injection rate and other variables affected image quality for ION-exams. Patient electronic medical records were reviewed to identify any adverse events related to CTA-TA or ION-IVA. RESULTS: 17 (∼0.2%) of 7401 exams were ION-exams. ION-exam CMI rates varied between 2.5 and 4 ml/s. Mean attenuation was 312 HU (SD 88 HU) and mean CNR was 25 (SD 9.9). A strong positive linear association between attenuation and injection rate was found. No immediate or delayed complications related to the ION-exams, or intraosseous needle use in general, occurred. CONCLUSION: For CTA-TA, ION-IVA appears to be a safe and effective route for CMI at rates up to 4 ml/s.

Prostate brachytherapy seed migration to the heart seen on cardiovascular computed tomographic angiography.

Brachytherapy consists of placing radioactive sources into or adjacent to tumors, to deliver conformal radiation treatment. The technique is used for treatment of primary malignancies and for salvage in recurrent disease. Permanent prostate brachytherapy seeds are small metal implants containing radioactive sources of I-125, Pd-103, or Cs-131 encased in a titanium shell. They can embolize through the venous system to the lungs or heart and subsequently be detected by cardiovascular computed tomography. Cardiovascular imagers should be aware of the appearance of migrated seeds, as their presence in the chest is generally benign, so that unnecessary worry and testing are avoided. We report a case of a patient who underwent brachytherapy for prostate cancer and developed a therapeutic seeds embolus to the right ventricle.

Gingerol-derivatives: emerging new therapy against human drug-resistant MCF-7.

Cancer chemotherapies have been improved dramatically over the last two decades. In the case of human breast cancer, the combination chemotherapeutic protocol, cyclophosphamide (CPA), doxorubicin (DOX), and 5-fluorouracil (5-FU) (CDF), is often used. Nevertheless, the clinical usefulness of CDF is limited by its remarkably low therapeutic window and frequent eruption of resistance. These limitations prompted our search for a more effective and safe drug candidate that may raise the therapeutic benefits for breast cancer patients. Gingerols' wide therapeutic indices as well as their high efficacy in the suppression of carcinogenesis are well established. However, no thorough study to date has profiled their antibreast cancer activities in depth. Therefore, the aims of the present study are to evaluate the antibreast cancer activities of gingerols in comparison to CDF and to gain insight into the structure activity relationships (SARs) responsible for the observed effect using a breast cancer cell model, MCF-7. Our data revealed that 6-gingerol showed the highest anticancer potency that is superior to that of CDF with IC50 = 30.4 µM. Guided by these results, semisynthetic modifications of 6-gingerol have been carried out to characterize 6-gingerol's SARs. The obtained results showed that the acquisition of free hydroxyl group in the aliphatic side chain of 6-gingerol is essential for the antibreast cancer activity. Likewise, the length of aliphatic side chain in 6-gingerol is optimum for its anticancer activity because any decrease in the side chain length resulted in a dramatic loss of anticancer activity. Additionally, allylation of phenolic group has shown antibreast cancer activity superior to that of 6-gingerol per se. Conversely, methylation or isoprenylation of phenolic group has led to a potential decrease in the anticancer activity, whereas loss of aromaticity resulted in a complete loss of 6-gingerol's cytotoxic activity. Collectively, the present results would simplify drug design to allow safer and more effective antibreast cancer pharmaceuticals to be designed.